公开(公告)号：US20180238908A1

公开(公告)日：2018-08-23

申请号：US15750327

申请日：2016-07-21

申请人： KRAN LIFE SCIENCES LLP

发明人： Krtin Kanna NITHIYANANDAM

IPC分类号： G01N33/68 ,  A61K47/68 ,  A61K47/69 ,  A61K49/00 ,  A61K49/04 ,  A61K49/10 ,  A61K49/18

CPC分类号： G01N33/6896 ,  A61K47/6879 ,  A61K47/6923 ,  A61K47/6929 ,  A61K49/0002 ,  A61K49/0428 ,  A61K49/108 ,  A61K49/1824 ,  A61K49/1881 ,  B82Y5/00 ,  G01N2333/4709

摘要： An amyloidogenic peptide biospecific agent comprises a nanoparticle which is visible under near infrared (NIR) and/or using Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT). The biospecific agent further comprises at least one antibody or antigen binding fragment thereof, which is immunospecific for a transferrin receptor and an amyloidogenic peptide.

公开(公告)号：US20180072783A1

公开(公告)日：2018-03-15

申请号：US15589585

申请日：2017-05-08

申请人： Zyngenia, Inc

发明人： Viktor ROSCHKE ,  David Lafleur ,  David M. Hilbert ,  Peter Kiener

IPC分类号： C07K14/47

CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6843 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6879 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/3046 ,  C07K16/32 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2319/01 ,  C07K2319/30 ,  C12N9/0002

摘要： Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.

公开(公告)号：US20170355779A1

公开(公告)日：2017-12-14

申请号：US15526888

申请日：2015-11-26

申请人： Zymeworks Inc.

发明人： Grant Raymond Wickman ,  Gordon Yiu Kon Ng ,  Nina E. Weisser

IPC分类号： C07K16/32 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28

CPC分类号： C07K16/32 ,  A61K39/395 ,  A61K47/6803 ,  A61K47/6855 ,  A61K47/6869 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

摘要： Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

公开(公告)号：US20170281767A1

公开(公告)日：2017-10-05

申请号：US15623890

申请日：2017-06-15

申请人： IBC Pharmaceuticals, Inc.

发明人： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/32

CPC分类号： A61K39/39558 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/48676 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

公开(公告)号：US20170114150A1

公开(公告)日：2017-04-27

申请号：US15382329

申请日：2016-12-16

申请人： Hoffmann-La Roche Inc.

发明人： Ulrich BRINKMANN ,  Guy GEORGES ,  Johannes AUER ,  Wilma LAU

IPC分类号： C07K16/44 ,  C07K16/28

CPC分类号： C07K16/44 ,  A61K47/549 ,  A61K47/62 ,  A61K47/6803 ,  A61K47/6879 ,  C07K16/2881 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/624

摘要： The invention provides anti-BRDU antibodies and methods of using the same.

公开(公告)号：US09567403B2

公开(公告)日：2017-02-14

申请号：US14452402

申请日：2014-08-05

申请人： BIO-THERA SOLUTIONS, LTD., CO.

发明人： Xiaoyun Wu ,  Shengfeng Li ,  Chenchao Xu

IPC分类号： C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  A61K47/48

CPC分类号： C07K16/30 ,  A61K47/48384 ,  A61K47/48561 ,  A61K47/48676 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6879 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/92

摘要： Provided are bispecific antibodies having a full-size antibody portion with two light chains and two heavy chains, wherein the two heavy chains each is fused to a single-chain variable fragment (scFv) portion. In certain embodiments, the full-size antibody has specificity to EGFR and the scFv has specificity to VEGF.

摘要翻译： 提供具有全长抗体部分的双特异性抗体，其具有两条轻链和两条重链，其中两条重链各自与单链可变片段（scFv）部分融合。 在某些实施方案中，全长抗体对EGFR具有特异性，并且scFv对VEGF具有特异性。

公开(公告)号：US20160287732A1

公开(公告)日：2016-10-06

申请号：US14942315

申请日：2015-11-16

申请人： IMMUNOMEDICS, INC.

发明人： Otto C. Boerman ,  Sandra Heskamp ,  Chien-Hsing Chang ,  William J. McBride ,  David M. Goldenberg

IPC分类号： A61K51/04 ,  A61K39/395 ,  A61K45/06 ,  C07K16/30 ,  C07K16/44

CPC分类号： A61K51/0495 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/595 ,  A61K47/6879 ,  A61K47/6891 ,  A61K51/088 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2319/035 ,  C12N15/85

摘要： The present invention relates to methods and compositions for pretargeting delivery of alpha-emitting radionuclides, such as 213Bi or 225AC to a target cell or tissue, such as a cancer cell or a tumor. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for a hapten; and b) administering a hapten-conjugated targetable construct that is labeled with an alpha-emitting radionuclide. More preferably, the bispecific antibody is rapidly internalized into the target cell, along with the radionuclide. In most preferred embodiments, the bispecific antibody is made as a dock-and-lock (DNL) complex.

摘要翻译： 本发明涉及用于预靶向将靶向细胞或组织例如癌细胞或肿瘤的α发射放射性核素（例如213Bi或225AC）递送的方法和组合物。 在优选的实施方案中，预靶向方法包括：a）施用包含肿瘤相关抗原（TAA）的至少一个结合位点和半抗原的至少一个结合位点的双特异性抗体; 和b）施用用α-发射放射性核素标记的半抗原共轭的可靶向构建体。 更优选地，双特异性抗体与放射性核素一起快速内化到靶细胞中。 在最优选的实施方案中，双特异性抗体被制备为对接和锁定（DNL）复合物。

公开(公告)号：US20160244520A1

公开(公告)日：2016-08-25

申请号：US15004791

申请日：2016-01-22

申请人： Abbvie Inc.

发明人： Robert J. Padley ,  Paul M. Peloso ,  Ahmed A. Othman

IPC分类号： C07K16/24 ,  A61K9/00 ,  A61K9/19 ,  A61K47/48 ,  A61K39/395 ,  A61K31/519

CPC分类号： C07K16/244 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/519 ,  A61K39/3955 ,  A61K47/6879 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/241 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/64 ,  C07K2317/76

摘要： Proteins that bind IL-17 and TNF-α are described along with their use in compositions and methods for treating psoriatic arthritis.

摘要翻译： 描述了结合IL-17和TNF-α的蛋白质及其在治疗牛皮癣关节炎的组合物和方法中的用途。

公开(公告)号：US20150353639A1

公开(公告)日：2015-12-10

申请号：US14761895

申请日：2013-05-20

申请人： Genentech, Inc.

发明人： Ryan Jefferson Watts ,  Joy Yu Zuchero ,  Jessica Couch ,  Mark Dennis

IPC分类号： C07K16/28 ,  C07K16/46 ,  A61K39/395 ,  A61K47/48 ,  C07K16/44 ,  A61K35/18 ,  C07K16/40

CPC分类号： A61K39/3955 ,  A61K35/18 ,  A61K39/39583 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2881 ,  C07K16/40 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

摘要： The present disclosure relates to compositions and methods for improving the safety of blood-brain barrier receptor-mediated blood-brain barrier transport.

摘要翻译： 本公开涉及用于改善血脑屏障受体介导的血脑屏障转运的安全性的组合物和方法。

公开(公告)号：US20150231241A1

公开(公告)日：2015-08-20

申请号：US14703082

申请日：2015-05-04

申请人： IBC Pharmaceuticals, Inc.

发明人： Chien-Hsing Chang ,  David M. Goldenberg ,  Edmund A. Rossi ,  Diane Rossi

IPC分类号： A61K39/395 ,  A61K47/48 ,  A61K45/06 ,  C07K16/32 ,  C07K16/28

CPC分类号： A61K39/39558 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2833 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2+ cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.

摘要翻译： 本发明涉及使用包含Trop-2（EGP-1）的至少一个结合位点和CD3的至少一个结合位点的双特异性抗体的组合物和方法。 双特异性抗体可用于诱导针对Trop-2表达肿瘤的免疫应答，例如食道癌，胰腺癌，肺癌，胃癌，结肠癌，直肠癌，膀胱癌，乳腺癌，卵巢癌，子宫癌，肾癌或前列腺癌。 所述方法可以包括单独施用双特异性抗体或与一种或多种治疗剂如抗体 - 药物偶联物，干扰素（优选干扰素-α）和/或检查点抑制剂抗体一起施用。 双特异性抗体能够靶向效应T细胞，NK细胞，单核细胞或嗜中性粒细胞以诱导白细胞介导的Trop-2 +癌细胞的细胞毒性。 通过共同给予干扰素，检查点抑制剂抗体和/或ADC来增强细胞毒性免疫应答。